Suppr超能文献

作为内分泌学家应对 COVID-19。

Encountering COVID-19 as Endocrinologists.

机构信息

Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Endocrinol Metab (Seoul). 2020 Apr 23;35(2):197-205. doi: 10.3803/EnM.2020.35.2.197. Print 2020 Jun.

Abstract

The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation.

摘要

由于新型冠状病毒病(COVID-19),即由严重急性呼吸系统综合征冠状病毒 2 引起的疾病,世界正进入灾难和混乱的时代。自 2019 年 12 月在中国武汉首次出现以来,COVID-19 已席卷亚洲,并传播到世界各地,包括欧洲和北美。截至 2023 年 4 月 13 日,全球已有 1773084 人感染,111652 人死于 COVID-19,每天都有新的感染记录创下新高。根据迄今为止收集的数据,COVID-19 重症甚至死亡的主要危险因素是糖尿病和高血压等基础疾病。随着全球糖尿病患病率的持续增加,糖尿病等内分泌疾病患者以及因肾上腺功能不全或垂体功能减退而长期接受皮质类固醇治疗的患者,COVID-19 的预后较差。作为内分泌学家,我们想简要回顾一下 COVID-19 与内分泌疾病之间关系的现有知识,并讨论在这种全球威胁的情况下,我们可以为患有内分泌疾病的患者的安全和健康做些什么。

相似文献

1
Encountering COVID-19 as Endocrinologists.作为内分泌学家应对 COVID-19。
Endocrinol Metab (Seoul). 2020 Apr 23;35(2):197-205. doi: 10.3803/EnM.2020.35.2.197. Print 2020 Jun.
4
Features of severe COVID-19: A systematic review and meta-analysis.严重 COVID-19 的特征:系统评价和荟萃分析。
Eur J Clin Invest. 2020 Oct;50(10):e13378. doi: 10.1111/eci.13378. Epub 2020 Aug 29.

引用本文的文献

本文引用的文献

2
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
3
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
5
Coronavirus Disease-19: The First 7,755 Cases in the Republic of Korea.新型冠状病毒肺炎:韩国首批7755例病例
Osong Public Health Res Perspect. 2020 Apr;11(2):85-90. doi: 10.24171/j.phrp.2020.11.2.05.
6
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19:单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验